Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax
Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax
复制标题
DOI：
10.1016/j.micinf.2007.08.002
复制
发表时间：
2007-10-01
影响因子：
5.8
通讯作者：
Merkel, Tod
中科院分区：
文献类型：
--
作者：
Klinman, Dennis M.;Currie, Debra;Merkel, Tod
正在开发改进的疫苗和佐剂，以减少涉及雾化炭疽孢子的恐怖袭击所造成的威胁。然而，关于吸入暴露于炭疽孢子后诱导粘膜免疫与全身免疫对宿主生存的相对益处仍然存在不确定性。这项工作检查了将许可的人类疫苗（吸附炭疽疫苗，AVA）与 CpG 寡脱氧核苷酸 (ODN) 佐剂腹膜内或鼻内注射给 A/J 小鼠的效果。结果表明，对吸入性炭疽的保护与诱导强烈的全身免疫反应而不是粘膜免疫反应相关，并且证明添加 CpG ODN 可以显着改善和加速保护作用。 (c) 2007 年 Elsevier Masson SAS。版权所有。
Improved vaccines and adjuvants are being developed to reduce the threat posed by a terrorist attack involving aerosolized anthrax spores. Nevertheless, uncertainty persists concerning the relative benefits of inducing mucosal vs systemic immunity to host survival following inhalational exposure to anthrax spores. This work examines the effect of delivering the licensed human vaccine (anthrax vaccine adsorbed, AVA) combined with a CpG oligodeoxynucleotide (ODN) adjuvant intraperitoneally or intranasally to A/J mice. Results indicate that protection from inhalational anthrax correlates with the induction of a strong systemic rather than mucosal immune response, and demonstrate that protection is significantly improved and accelerated by the addition of CpG ODN. (c) 2007 Elsevier Masson SAS. All rights reserved.